We are live on ! Find out more

Catalyst Pharmaceutical

CPRX

87 hedge funds and large institutions have $180M invested in Catalyst Pharmaceutical in 2015 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 14 closing their positions.

New

Increased

Maintained

Reduced

Closed

684% more call options, than puts

Call options by funds: $588K | Put options by funds: $75K

150% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 14

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

32% more funds holding

Funds holding: 66 → 87 (+21)

7% more capital invested

Capital invested by funds: $168M → $180M (+$11.3M)

Holders

Holders Change

+21

Holders Change %

+31.82%

% of All Funds

2.34%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

$588K

Puts

$75K

Net Calls

+$513K

Net Calls Change

+$466K

Top Buyers

1	Federated Hermes Pittsburgh, Pennsylvania	+$10.3M
2	BFA BlackRock Fund Advisors San Francisco, California	+$7.14M
3	CCM Consonance Capital Management New York	+$2.66M
4	State Street Boston, Massachusetts	+$2.46M
5	BIT BlackRock Institutional Trust San Francisco, California	+$2.26M

Top Sellers

1	Point72 Asset Management Stamford, Connecticut	-$12.4M
2	Morgan Stanley New York	-$1.6M
3	PA Perceptive Advisors New York	-$1.39M
4	Susquehanna International Group Bala Cynwyd, Pennsylvania	-$1.26M
5	BBA Baker Bros. Advisors New York	-$916K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
76	76 BlackRock New York	$8K	+$7.49K	+1,879	New
77	AIM 77 Advantage Investment Management Cedar Rapids, Iowa	$6K	–	–	–
78	78 Bank of Montreal Toronto, Ontario, Canada	$6K	–	–	–
79	79 Invesco Atlanta, Georgia	$6K	+$5.51K	+1,382	New
80	80 Walleye Trading New York	$6K	+$5.58K	+1,400	New
81	81 Barclays London, United Kingdom	$6K	+$5.74K	+1,441	New
82	82 Citigroup New York	$4K	+$3.79K	+951	+3,396%
83	83 PNC Financial Services Group Pittsburgh, Pennsylvania	$4K	+$3.99K	+1,000	New
84	MTIP 84 Magee Thomson Investment Partners San Diego, California	$4K	+$4.01K	+1,007	New
85	85 Acadian Asset Management Boston, Massachusetts	$2K	+$2.19K	+550	New
86	86 Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada	$205	+$198K	+49,577	New
87	EMFAT 87 Emerald Mutual Fund Advisers Trust Leola, Pennsylvania	–	-$533K	-150,000	Closed
88	BCM 88 BlueCrest Capital Management St Helier, Jersey	–	-$516K	-119,054	Closed
89	ARTA 89 A.R.T. Advisors New York	–	-$398K	-92,100	Closed
90	WPP 90 Whalerock Point Partners Providence, Rhode Island	–	-$367K	-84,900	Closed
91	PSC 91 Piper Sandler & Co Minneapolis, Minnesota	–	-$217K	-50,000	Closed
92	92 Dimensional Fund Advisors Austin, Texas	–	-$201K	-46,438	Closed
93	93 Stifel Financial St. Louis, Missouri	–	-$152K	-35,000	Closed
94	94 Verition Fund Management Greenwich, Connecticut	–	-$100K	-23,050	Closed
95	95 Renaissance Technologies New York	–	-$92K	-21,227	Closed
96	CAS 96 CTC Alternative Strategies Chicago, Illinois	–	-$77.9K	-18,000	Closed
97	TC 97 TradeLink Capital Chicago, Illinois	–	-$75K	-17,220	Closed
98	EGM 98 Engineers Gate Manager New York	–	-$64K	-14,882	Closed
99	HCM 99 Highbridge Capital Management New York	–	-$64K	-14,728	Closed
100	100 Creative Planning Overland Park, Kansas	–	-$36K	-8,231	Closed

CPRX Hedge Fund Activity: Q2 2015 in Review

87 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2015, worth a combined $180M — up 6.7% from $168M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CPRX positions and 14 closed out — a net gain of 21 holders — while 24 added to existing stakes and 18 trimmed.

The largest buyer was Federated Hermes, adding an estimated $10.3M. The largest seller was Point72 Asset Management, cutting an estimated $12.4M.

87 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2015, up from 66 in Q1 2015.
Funds reported $180M of Catalyst Pharmaceutical stock for Q2 2015, up 6.7% quarter-over-quarter.
35 funds opened new Catalyst Pharmaceutical positions in Q2 2015 and 14 closed out, a net change of +21 holders.
The largest Catalyst Pharmaceutical buyer in Q2 2015 was Federated Hermes, an estimated $10.3M added.
The largest Catalyst Pharmaceutical seller in Q2 2015 was Point72 Asset Management, an estimated $12.4M sold.

Based on aggregated 13F filings for Q2 2015.

Catalyst Pharmaceutical CPRX